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Objective: To investigate adverse pregnancy outcomes in non-obese women with polycystic ovary syndrome (PCOS) compared with obese-
PCOS and control groups.
Methods: Women with PCOS who underwent assisted reproductive technology (ART) from August, 2003 to December, 2007, were considered. 
A total of 336 women with PCOS were included in the study group and 1,003 infertile women who had tubal factor as an indication for ART 
were collected as controls. They were divided into four groups: a non-obese PCOS group, obese-PCOS group, non-obese tubal factor group, 
and obese tubal factor group, with obesity defined by a body mass index over 25 kg/m
2, and reviewed focusing on the basal characteristics, 
ART outcomes, and adverse pregnancy outcomes. 
Results: There was no difference among the groups’ the clinical pregnancy rate or live birth rate. Regarding adverse pregnancy outcomes, the 
miscarriage rate, multiple pregnancy rate, and prevalence of preterm delivery and pregnancy induced hypertension were not different among 
the four groups. The incidence of small for gestational age infant was higher in the PCOS groups than the tubal factor groups (p<0.02). On the 
other hand, the morbidity of gestational diabetes mellitus (GDM) was not high in the non-obese PCOS group but was in the obese groups. And 
in the obese PCOS group, the newborns were heavier than in the other groups (p<0.02).
Conclusion: Non-obese PCOS presents many differences compared with obese PCOS, not only in the IVF-parameters but also in the morbidity 
of adverse pregnancy outcomes, especially in GDM and fetal macrosomia. 
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Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine 
disorder in reproductive aged women [1], diagnosed by any two of 
the following three: menstrual irregularity with oligo-anovulation, 
clinical or biochemical hyperandrogenism, and polycystic ovarian 
features on ultrasonogram (Rotterdam criteria, 2003). It is character-
ized clinically by menstrual irregularity, hirsutism, biochemically hy-
perandrogenism, high serum LH, and insulin resistance, and obesity 
[2]. Those women suffer from not only menstrual irregularity and in-
fertility but also several obstetric complications and long term meta-
bolic disturbance [3]. Furthermore, some investigators have pro-
posed that the offspring of a PCOS mother might be at an increased 
risk of several adult disorders in later life [4]. 
In terms of adverse pregnancy outcomes, gestational diabetes 
(GDM), fetal macrosomia, small for gestational age (SGA) infant, pre-
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term labor, and preeclampsia are considered to be complications of 
PCOS pregnancy [5]. However, not only PCOS, but also obesity, which 
is frequently accompanied by PCOS, is an independent risk factor of 
these obstetric complications [6]. 
Many investigators have given attention to obese women with PCOS 
and the relation of PCOS and obesity. Some researchers reported more 
severe insulin resistance, worse ovulatory dysfunction, and higher 
serum testosterone levels in obese PCOS women [7]. In addition, a 
higher incidence of GDM was described in obese PCOS women than 
non-obese ones [8]. However, it is debatable whether these compli-
cations are as severe in non-obese PCOS women as in obese PCOS 
women. Therefore, we aimed to investigate the prevalence of adver-
se pregnancy outcomes in non-obese women with PCOS by com-
parison with control groups.
Methods
1. Patients
From August 1, 2003 to December 31, 2007, PCOS women who had 
their infertility treated with  controlled ovarian hyperstimulation (COH) 
with IVF or superovulation were included for the study group. PCOS 
was defined by the 2003 Rotterdam criteria, and a total of 336 assist-
ed reproductive technology (ART) cycles were also included, retro-
spectively. As a control group, women who had taken ART during 
same period due to tubal factor infertility that presented at least uni-
lateral tubal obstruction, were collected. But women who had both 
PCOS and tubal factor were excluded. 
These two groups were divided into 4 groups by body mass index 
(body mass index [BMI] over 25 kg/m
2 or not), i.e., obese PCOS (A), 
non-obese PCOS (B), obese tubal factor (C), and non-obese tubal fac-
tor (D) groups.
2. ART protocols
The ovarian stimulation was done with gonadotropins in the usual 
way as extensively described. Briefly, the basal serum hormonal level 
was measured at menstrual day 2 or 3, and the absence of growing 
follicles (over 10 mm in size) or pelvic organic abnormalities was 
checked by trans-vaginal ultrasonogram (TVS). Gonadotropins were 
applied with the monitoring of the serum estradiol level and grow-
ing follicles by TVS. When two or more follicles reached 18 mm diam-
eter, 5,000 units of hCG (IVF-C®; LG life Science, Seoul, Korea) was ad-
ministered. IUI was done about 34-36 hours after hCG injection. Lu-
teal support was done with vaginal progesterone tablets (Utroges-
tan® 100 mg tid/day; Laboratories Besins International, Paris, France) 
for 14 days.
In COH-IVF cycles, the patients underwent pituitary down-regula-
tion with a low-dose GnRH agonist (Lucrin® 1 mg/day; Abbott Lab., 
Chicago, IL, USA or Decapeptyl® 0.1 mg/day; Ferring Parmarceuticals, 
Saint-Prex, Switzland) from the mid-luteal period of the previous cy-
cle or daily GnRH antagonist (Orgalutran® 0.25 mg/day; Schering-
Plough, Whitehouse Station, NJ, USA or Cetrotide® 0.25 mg/day; 
Merk KgaA, Darmstadt, Germany) applied when the dominant folli-
cle reached 12 to 13 mm. When two or more follicles reached 18 mm 
in diameter, 10,000 units of hCG (Ovidrel®; Industria Farmaceutica Se-
rono SpA, Roma, Italy) was administered. Trans-vaginal ultrasound 
guided ovum pick-up (OPU) was performed 34-36 hours later and 
then the maturity and quality of the retrieved oocytes was evaluated. 
According to the motility and the number of sperm and oocytes, in-
semination (conventional IVF) or microinjection (ICSI) was carried out 
4-6 hours after OPU. After several days of in vitro culture, 4 or fewer 
selected embryos were transferred (ET) for each cycle. For luteal sup-
port, daily intramuscular injection of progesterone (Progesterone®; 
Watson Phar maceuticals Inc., Corona, CA, USA) was started on the 
OPU day to first test serum β-hCG in non-pregnant cycles or in the 
7th to 8th gestational weeks in pregnant cycles.
3. Measurement of outcomes
All parameters and pregnancy outcomes were collected from the 
medical records, retrospectively. 
The clinical pregnancy rate and live birth rate were mea sured and 
the IVF parameters and implantation rate were collected. Adverse 
pregnancy outcomes such as multiple pregnancy, miscarriage, pre-
term delivery, GDM, pregnancy induced hypertension (PIH), fetal ma-
crosomia, and SGA were reported and the incidence of each compli-
cation was measured. 
The implantation rate was calculated by the number of gestational 
sacs per transferred embryo and a clinical pregnancy was defined as 
the presence of a G-sac on the trans-vaginal ultrasound at gestation-
al weeks 5 to 7. 
GDM screening with a 50 g oral glucose tolerance test (OGTT) was 
performed at 24 weeks of gestation. When a glucose value reached 
to 130-140 mg/dL, a further confirmatory test, i.e., 3 hours 100 g OGTT, 
was recommended, and GDM was diagnosed according to the pro-
tocol of the American Diabetic Association [9]. PIH was described as 
hypertension with a systolic blood pressure over 140 mm Hg or dia-
stolic blood pressure over 90 mm Hg, with or without proteinuria, 
developing after 20 weeks of gestation. The birth weight of a new-
born over 4,000 g or >90 % of mean weight of gestational age (GA) 
was defined as fetal macrosomia and <10% of GA was diagnosed as 
SGA. Preterm birth referred to a birth occurring before 37 complete 
weeks of gestation.
4. Analysis
Statistical analysis was performed using SPSS ver. 16.0 (SPSS Inc., www.eCERM.org
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Chicago, IL, USA). Each variable is presented as mean (±SD). ANOVA 
with the Bonferroni post-hoc test was used wherever appropriate. A 
p-value of <0.05 was considered statistically significant.
Results 
The PCOS women were collected for a total of 336 cycles of ART, in-
cluding 64 cycles of the obese group (A) and 272 cycles of the non-
obese group (B). The control group included 1,003 cycles with 117 for 
group C and 886 for group D. The mean BMI of each group was about 
27.5 kg/m
2 (obese groups; groups A and C) and 20.5 kg/m
2 (non-
obese groups; groups B and D). The non-obese PCOS group (B) was 
one year younger (mean age was 31.2±2.7 years) than the tubal fac-
tor groups (C and D), but there was no difference in age between the 
two PCOS groups (A and B). The PCOS groups (A and B) had a higher 
proportion of primary infertility (62.0% vs. 41.2%, p<0.001) than the 
tubal factor groups. The duration of infertility was near 40 months or 
less, except for group C (46.2±35.9 months) and the basal serum 
FSH levels of each group were similar, near 7.0 mIU/mL or less, except 
group D (7.2±2.1 mIU/mL) (Table 1).
In the IVF cycles, the number of retrieved oocytes was higher in the 
non-obese PCOS group than the control groups (groups C and D), 
but the fertilization rate and number of good embryos were lower 
than those of the tubal groups (No. of retrieved oocytes was 19.2±9.4 
vs. 12.9±8.3, p<0.001, fertilization rate was 59.1±18.0 vs. 67.4±19.7, 
p<0.001, and number of good embryos was 2.08±1.30 vs. 2.39±1.20, 
p=0.016). The PCOS groups showed a better implantation rate than 
the tubal factor groups, especially in the comparison of groups B and 
D (22.2% vs. 13.1%, p<0.001) (Table 2).
There was no difference among the groups in the clinical pregnan-
cy rate or live birth rate. As for the adverse pregnancy outcomes, the 
multiple pregnancy rate, miscarriage rate, and prevalence of preterm 
delivery did not differ among the 4 groups. The morbidity of GDM was 
definitely higher (10.53% and 8.57% vs. 1.12% and 1.76%, p=0.014) 
in the obese groups (groups A and C) than the non-obese groups 
(groups B and D) and the morbidity of mothers with SGA was higher 
Table 1. Patient characteristics of each group
Groups
PCOS (n=366) Tubal factor (n=1,003)
p-value
Obese  Non-obese  Obese  Non-obese 
Cycles (n) COH-IVF 25 114   71 570
Cryo-ET 18   58   87 255
Superovulation 21 100     9   61
Total 64 272 117 886
Age (yr) 31.6±3.1  31.2±2.7
a 32.2±3.2 32.5±2.8 <0.001
BMI (kg/m
2)   27.46±2.42
b  20.45±2.02   27.50±2.00
b  20.58±1.97 <0.001
Primary infertility (%) 53.1
c 62.0
c  42.2 33.8 <0.001
Duration of infertility (mo)    39.8±24.2   39.0±25.5     46.2±35.9
d   38.6±29.2 0.049
Basal FSH (mIU/mL)   5.7±1.9   6.5±1.8   7.0±2.1    7.2±2.1
e <0.001
Values presented as mean±SD. 
PCOS, polycystic ovary syndrome; COH-IVF, controlled ovarian hyperstimulation with in vitro fertilization; ET, embryo transfer; BMI, body mass index.
anon-obese PCOS vs. tubal factor; 
bobese vs. non-obese; 
cPCOS vs. tubal factor; 
dobese vs. non-obese tubal factor; 
enon-obese tubal factor vs. PCOS.
Table 2. IVF parameters of each group
Groups
PCOS (n=366) Tubal factor (n=1,003)
p-value
Obese  Non-obese  Obese  Non-obese 
Fresh COH-IVF cycles (n) 25 114   71 570
   E2 (pg/mL) on hCG day 1,710.4±1,242.6 2,347.5±1,569.9 1,692.8±1,083.6 2,113.4±1,341.7 NS
   No. of retrieved oocytes 17.0±8.9 19.2±9.4
a 12.3±9.2  13.0±8.2  <0.001
   Fertilization rate (%) 64.2±18.6 59.1±18.0
b 71.7±20.5  66.8±19.6  <0.001
Total IVF cycles (n) 43 172 108 825
   No. of good embryos 2.26±1.03 2.08±1.30
c 2.47±1.03  2.38±1.19  0.018
   No. of transferred embryos 3.12±0.60 3.12±0.80 3.05±0.84 3.22±0.82 NS
   Implantation rate (%) 21.5     22.2
d      17.9       13.1  <0.001
Values presented as mean±SD.
PCOS, polycystic ovary syndrome; COH-IVF, controlled ovarian hyperstimulation with in vitro fertilization; NS, not significant. 
a,b,c,dnon-obese PCOS vs. tubal factor.  doi: 10.5653/cerm.2011.38.2.103
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in the PCOS groups (21.1% and 20.2% vs. 11.5%, p=0.012) than the 
tubal factor groups. In the obese PCOS group, newborns were heavi-
er than in the other groups (While the rate of fetal macrosomia was 
21.05% in group A, it was under 5% in the other groups, p<0.001). 
On the other hand, the incidences of PIH of each group were not dif-
ferent (Table 3).
Discussion 
Several studies have reported on the pregnancy complications of 
PCOS women, but most were performed in western countries. This 
study differs from previous reports in several key ways. First, it was 
performed in Asia, specifically South Korea. Asian women are slightly 
different from western women in the feature of PCOS, obesity, and 
their complications. The other distinction of this study is the sub-
grouping of PCOS women by BMI to investigate the influence of 
obesity on adverse pregnancy outcomes, which are considered com-
plications of PCOS.
The WHO defined obesity as BMI over 30 kg/m
2 [10]. This was based 
on coincidence of obesity and several adult diseases such as Type 2 
diabetes and cerebro-vascular accidents [11]. However, the preva-
lence of obesity in Asian populations is lower and the health risks as-
sociated with obesity occur at a lower BMI than that of western peo-
ple [12,13]. Thus the definition of obesity in this study is a BMI over 
25 kg/m
2 following the new criteria of “WHO – The Asia-Pacific Per-
spective” [13]. The Republic of Korea’s National Nutrition Survey of 
2008 [14], announced about 25% of reproductive aged women were 
classified as obese (BMI>25 kg/m
2) by the new criteria of obesity for 
Asians. 
In the PCOS group, the younger age and lower FSH levels may re-
sult from earlier visits to the infertility clinic due to menstrual irregu-
larity compared with the other infertile groups. 
In the non-obese PCOS groups, more oocytes were retrieved, but 
the fertility rate and good embryo rate was significantly lower than 
for the tubal factor groups. As a result, we could agree with Qiao and  
Feng [15]’s opinion that PCOS is associated with poor quality oocytes. 
However, this tendency was not significant in the obese PCOS group. 
Unfortunately, we could not explain why this phenomenon occurred. 
Despite the poor quality of oocytes, the implantation rate was higher 
in the PCOS group than the tubal factor group. This could be because 
of the unfavorable environment to implantation in tubal factor groups 
such as the presence of inflammatory cytokines from hydrosalpinx.
Regarding adverse pregnancy outcomes, the abortion rate of the 
PCOS groups was not higher than the other infertile women (tubal 
factor groups), contrary to the findings of a previous paper, which re-
ported that PCOS women showed more frequent early pregnancy 
loss (about 40%) than the general population [16]. Some investiga-
tors have suggested that this is caused by elevated LH in PCOS [17], 
while another said that it is due to ovulation inducing agents such as 
clomiphene citrate, which has an anti-estrogenic effect on the endo-
metrium [18], and another asserted that it is caused by obesity ac-
companying PCOS [19]. However, all the patients of this study under-
went various forms of ART including ovulation induction or super-
ovulation, but the miscarriage rate was not elevated in the PCOS 
groups and it was the same regardless of BMI. 
Normal pregnancy itself induces an insulin resistant state and insu-
lin resistance is thought to be the etiology of PCOS. Therefore, many 
studies have suggested that women with PCOS are likely to develop 
GDM and macrosomia, which is a complication of maternal hyper-
glycemia [6]. However, the prevalence of GDM and LGA was not high-
er in either PCOS group. GDM frequently developed in the obese 
subgroups of each group, i.e., group A and C, and the incidence of 
LGA was higher in only the obese PCOS group. Hence, we assumed 
that the results of previous published studies presenting the higher 
incidence of GDM and LGA of PCOS women was mainly caused by 
obesity, which was likely to occur with PCOS. Thus we suggest that 
non-obese PCOS is not the risk factor for GDM or LGA.
PCOS can be expected to be a risk factor of PIH, due to its metabolic 
and vascular status. A meta-analysis of eight studies found that wom-
en with PCOS showed a significantly higher incidence of PIH [5], but 
other larger studies reported that not PCOS itself, but nulliparity that 
may be caused by anovulatory infertility in PCOS women is a signifi-
cant risk factor for PIH [20]. In this study, even though the PCOS group 
consisted of a higher number of primary infertile women, i.e., nullipa-
rity, there was no difference in the incidence of PIH among the groups. 
SGA can also be expected to develop often in women with PCOS. 
The vascular status of PCOS, which possibly causes placental insuffi-






Obese Non-obese Obese Non-obese
Clinical pregnancy rate (%) 35.9 40.8 32.7 38.5 NS
Live birth rate (%) 29.7 32.7 25.6 29.9 NS
Miscarriage rate (%) 17.4 19.8 22.2 21.7 NS
Multiple pregnancy rate (%) 28.6 30.2 21.7 21.6 NS
Preterm delivery (%) 21.1 27.0 28.6 23.3 NS
GDM (%) 10.5
a 1.1  8.6
a 1.8       0.014
PIH (%) 0 5.6 5.7 5.3 NS
SGA (%) 21.1
b 20.2
b 0 11.5       0.012
LGA (%) 21.1
c 2.2  0 4.0  <0.001
PCOS, polycystic ovary syndrome; NS, not significant; GDM, gestational dia-
betes mellitus; PIH, pregnancy induced hypertension; SGA, small for gesta-
tional age; LGA, large for gestational age.
aObese vs. non-obese; 
bPCOS vs. tubal factor; 
cObese PCOS vs. non-obese 
PCOS and tubal factor. www.eCERM.org
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ciency and prenatal exposure to sex steroids [21], may bring out fetal 
growth retardation. However, the published studies presented con-
flicting results about the relationship between birth weight and PCOS 
[22]. This disparity may stem from the higher rate of LGA in pregnan-
cy of those with PCOS. In this study, we found a higher incidence of 
SGA in the PCOS group regardless of obesity.
Preterm birth can be higher in women with PCOS, due to the high-
er rate of multiple pregnancies from ovulation induction. However, in 
this study we could not find any differences in the prevalence of pre-
term birth and multiple pregnancies among the 4 groups. 
Regarding the long-term health problems of offspring, some inves-
tigators have suggested that the infants of PCOS mothers may be at 
an increased risk of several adult disorders, such as cardiovascular 
disease, type 2 diabetes, obesity, and hypertension [4]. Unfortunate-
ly, we could not follow up on the infants in this study, so a long-term 
follow up of the babies of mothers with PCOS should be performed 
in the future.
PCOS has various properties and presents in heterogeneous sub-
groups. Several adverse pregnancy outcomes that have been consid-
ered to be complications of PCOS are caused by not only PCOS itself, 
but in combination with other problems such as obesity. Though 
SGA developed in the PCOS group regardless of obesity, GDM and 
LGA did not develop as frequently in the non-obese PCOS group as 
in the obese PCOS group. Therefore, we suggest that the differentiat-
ed care of pregnant women with PCOS is needed according to the 
existence of obesity. For a more definite conclusion about the preg-
nancy complications of non-obese PCOS women, a large scale long-
term follow up study is warranted. 
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